Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-30
2011-08-30
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021400, C514S021500, C514S021600
Reexamination Certificate
active
08008259
ABSTRACT:
The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory are beneficial for treatment.
REFERENCES:
patent: 6723344 (2004-04-01), Sakiyama-Elbert et al.
patent: 2004/0072291 (2004-04-01), Carr et al.
patent: 2005/0048606 (2005-03-01), Wang et al.
patent: 06317587 (1994-11-01), None
patent: WO 92/02620 (1992-02-01), None
patent: WO 93/25684 (1993-12-01), None
patent: WO 9954470 (1999-10-01), None
patent: WO 02/066514 (2002-08-01), None
patent: WO 02062832 (2002-08-01), None
patent: WO 03/045998 (2003-06-01), None
patent: WO 2005/019266 (2005-03-01), None
Allen & Dawbarn “Clinical relevance of the neurotrophins and their receptors,” Clinical Science, 2006, 110, 175-191, especially pp. 175-181.
Massa et al. “Alzheimer's Therapeutics” J. Mol. Neuro., 2002, 19, 107-11.
Bibel et al. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & Development, 2000, 14: 2919-2937.
Bothwell, Mark. p75NTR: A receptor after all. Science, 272: No. 5261 (Apr. 26, 1996) 506-507.
Carter, Bruce D and Lewin, Gary R. Neutotrophins live let die: Does p75NTR decide? Neuron, 18: 187-190, Feb. 1997.
Chao, Moses V. Neurotrophin receptors: A window into neuronal differentiation. Neuron, 9: 583-593, Oct. 1992.
D'Mello et al. Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. USA, vol. 90, 10989-10993, Dec. 1993, Neurobiology.
Hu et al. NGF stimulates extensive neurite outgrowth from implanted dorsal root ganglion neurons following transplantation into the adult rat inner ear. Neurobiology of Disease, 18 (2005) 184-192.
Jakubowska-Dogru, Ewa and Gümüsbas Umut. Chronic intracerebroventricular NGF administration improves memory in young adult memory deficient rats. Neurosci. Letters. 382 (2005) 45-50.
Lee et al. The uniqueness of being a neurotrophin receptor. Current opinion in Neurobiology, 2001, 11:218-286.
Longo et al. Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor-dependent mechanism. Journal of Neuroscience Research, 48: 1-17 (1997).
Ma et al. Nerve growth factor receptor-mediated gene transfer. Molecular Therapy, vol. 9, No. 2, Feb. 2004, 270-281.
Maliartchouk et al. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. The Journal of Biological Chemistry, vol. 275,No. 14, Apr. 7, 9946-9956, 2000.
O'Leary, Paul D. and Hughes, Richard A. Design of potent peptide mimetics of brain-derived neurotrophic factor. The Journal of Biological Chemistry, vol. 278, No. 28, Jul. 11, 25738-25744, 2003.
Penkowa et al. Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury. Experimental Neurology, 181 (2003) 130-148.
Rønn et al. A simple procedure of quantification of neurite outgrowth based on stereological principles. Journal of Neuroscience Methods, 100 (2000) 25-32.
Salehi et al. Alzheimer's disease and NGF signaling. Journal of Neural Transmission (2004) 111: 323-345.
Shoval, Gal and Weizman, Abraham. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. European Neuropsychopharmacology, 15 (2005) 319-329.
Thomas, Kerrie and Davies, Alun. Neurotrophins: A ticket to ride for BDNF. Current Biology, vol. 15, No. 7, 2005, R262-R264.
Tuszynski et al. A phase 1 clinical trial of nerve growth factor gene therapy for alzheimer disease. Nature Medicine, vol. 11, No. 5, May 2005, 551-555.
Ullrich, Axel and Schlessinger, Joseph. Signal transduction by receptors with tyrosine kinase activity. Cell, vol. 61, 203-212, Apr. 20, 1990.
Walz et al. Short- and long-term memory are differentialy modulated by hippocampal nerve growth factor and fibroblast growth factor. Neurochemical Research, vol. 30, No. 2, Feb. 2005, 185-190.
Williams et al. Overcoming the inhibitors of myelin with a novel neurotrophin strategy. The Journal of Biological Chemistry, vol. 280, No. 7, Feb. 18, 5862-5869, 2005.
Xie et al. Nerve growth factor (NGF) loop 4 mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. The Journal of Biological Chemistry, vol. 275, No. 38, Sep. 22, 29868-29874, 2000.
Berezin Vladimir
Bock Elisabeth
Bradley Christina
Cooper Iver P.
Copenhagen University, Techtrans Unit
LandOfFree
Neurotrophin-derived peptide sequences does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurotrophin-derived peptide sequences, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotrophin-derived peptide sequences will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2677672